The market for breast implants is expected to grow modestly in the U.S. over the nest few years, but European sales won't climb much at all, Millennium Research Group concludes in a new report. Among the factors leading to only modest U.S. sales: A rigorous U.S. approval process and a duopoly between the two main competitors--Allergan ($AGN) and Mentor. The EU market for breast implants remains much smaller, Millennium notes, and dipped by more than 2% from 2010 to 2011, with further declines expected through 2016. Release